Hunan Jingfeng Pharmaceutical (000908) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hunan Jingfeng Pharmaceutical (000908) has a cash flow conversion efficiency ratio of -3.332x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥125.78 Million ≈ $18.41 Million USD) by net assets (CN¥-37.76 Million ≈ $-5.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 000908 market cap overview for the company's overall valuation and market capitalisation.
Hunan Jingfeng Pharmaceutical - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Hunan Jingfeng Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hunan Jingfeng Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hunan Jingfeng Pharmaceutical ranked by their cash flow conversion efficiency. Explore Hunan Jingfeng Pharmaceutical cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Research Institute of Building Sciences Group Co. Ltd A
SHG:603153
|
N/A |
|
TMK
KLSE:5330
|
N/A |
|
Forward Industries Inc
NASDAQ:FORD
|
-0.002x |
|
Supriya Lifescience Limited
NSE:SUPRIYA
|
0.051x |
|
Aces Electronics Co Ltd
TW:3605
|
0.035x |
|
SmartFinancial, Inc.
NYSE:SMBK
|
0.029x |
|
Cera Sanitaryware Limited
NSE:CERA
|
0.052x |
|
Jiangsu SINOJIT Wind Energy Technology Co Ltd
SHG:601218
|
0.011x |
Annual Cash Flow Conversion Efficiency for Hunan Jingfeng Pharmaceutical (1999–2024)
The table below shows the annual cash flow conversion efficiency of Hunan Jingfeng Pharmaceutical from 1999 to 2024. View Hunan Jingfeng Pharmaceutical share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥-15.13 Million ≈ $-2.21 Million |
CN¥-5.55 Million ≈ $-812.28K |
0.367x | +260.81% |
| 2023-12-31 | CN¥-153.68 Million ≈ $-22.49 Million |
CN¥35.06 Million ≈ $5.13 Million |
-0.228x | -139.76% |
| 2022-12-31 | CN¥214.83 Million ≈ $31.44 Million |
CN¥123.27 Million ≈ $18.04 Million |
0.574x | +51.85% |
| 2021-12-31 | CN¥327.73 Million ≈ $47.96 Million |
CN¥123.83 Million ≈ $18.12 Million |
0.378x | +188.76% |
| 2020-12-31 | CN¥638.18 Million ≈ $93.39 Million |
CN¥-271.68 Million ≈ $-39.76 Million |
-0.426x | -2385.47% |
| 2019-12-31 | CN¥1.94 Billion ≈ $284.15 Million |
CN¥36.17 Million ≈ $5.29 Million |
0.019x | -84.81% |
| 2018-12-31 | CN¥2.86 Billion ≈ $418.81 Million |
CN¥350.94 Million ≈ $51.35 Million |
0.123x | +110.21% |
| 2017-12-31 | CN¥2.60 Billion ≈ $380.45 Million |
CN¥151.65 Million ≈ $22.19 Million |
0.058x | +1136.37% |
| 2016-12-31 | CN¥2.61 Billion ≈ $382.27 Million |
CN¥12.32 Million ≈ $1.80 Million |
0.005x | -88.52% |
| 2015-12-31 | CN¥2.25 Billion ≈ $329.02 Million |
CN¥92.37 Million ≈ $13.52 Million |
0.041x | -80.17% |
| 2014-12-31 | CN¥994.04 Million ≈ $145.46 Million |
CN¥205.93 Million ≈ $30.13 Million |
0.207x | +131.95% |
| 2013-12-31 | CN¥5.31 Million ≈ $776.82K |
CN¥-3.44 Million ≈ $-503.70K |
-0.648x | -10996.71% |
| 2012-12-31 | CN¥-60.15 Million ≈ $-8.80 Million |
CN¥351.50K ≈ $51.44K |
-0.006x | +99.93% |
| 2011-12-31 | CN¥790.82K ≈ $115.72K |
CN¥-6.87 Million ≈ $-1.01 Million |
-8.689x | -3203.30% |
| 2010-12-31 | CN¥57.85 Million ≈ $8.46 Million |
CN¥-15.21 Million ≈ $-2.23 Million |
-0.263x | -122.84% |
| 2009-12-31 | CN¥100.67 Million ≈ $14.73 Million |
CN¥-11.88 Million ≈ $-1.74 Million |
-0.118x | -228.87% |
| 2008-12-31 | CN¥338.64 Million ≈ $49.55 Million |
CN¥31.02 Million ≈ $4.54 Million |
0.092x | -40.95% |
| 2007-12-31 | CN¥336.95 Million ≈ $49.31 Million |
CN¥52.26 Million ≈ $7.65 Million |
0.155x | -9.89% |
| 2006-12-31 | CN¥336.40 Million ≈ $49.23 Million |
CN¥57.90 Million ≈ $8.47 Million |
0.172x | +195.38% |
| 2005-12-31 | CN¥329.66 Million ≈ $48.24 Million |
CN¥-59.49 Million ≈ $-8.71 Million |
-0.180x | +60.83% |
| 2004-12-31 | CN¥339.45 Million ≈ $49.67 Million |
CN¥-156.37 Million ≈ $-22.88 Million |
-0.461x | -958.22% |
| 2003-12-31 | CN¥419.38 Million ≈ $61.37 Million |
CN¥22.51 Million ≈ $3.29 Million |
0.054x | +59.52% |
| 2002-12-31 | CN¥522.69 Million ≈ $76.49 Million |
CN¥17.59 Million ≈ $2.57 Million |
0.034x | -45.02% |
| 2001-12-31 | CN¥498.41 Million ≈ $72.93 Million |
CN¥30.50 Million ≈ $4.46 Million |
0.061x | +222.29% |
| 2000-12-31 | CN¥500.54 Million ≈ $73.24 Million |
CN¥-25.05 Million ≈ $-3.67 Million |
-0.050x | -278.13% |
| 1999-12-31 | CN¥485.43 Million ≈ $71.03 Million |
CN¥13.64 Million ≈ $2.00 Million |
0.028x | -- |
About Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more